Aburano T, Yokoyama K, Shuke N, Takayama T, Michigishi T, Tonami N, Hisada K, Unoura M, Kobayashi K
Department of Nuclear Medicine, Kanazawa University Hospital, Japan.
J Clin Gastroenterol. 1993 Dec;17(4):321-6. doi: 10.1097/00004836-199312000-00013.
Ninety-six patients with various diffuse hepatic diseases were observed using both 99mTc colloid and 99mTc iminodiacetic acid (IDA), focusing on the potential etiologies of the disease process as well as its chronicity and severity. The presence of acute hepatic disease was more sensitively depicted with 99mTc IDA than with 99mTc colloid. In chronic hepatic disease, on the other hand, 99mTc colloid and 99mTc IDA demonstrated a similar sensitivity. The potential etiology of the disease process (differential diagnosis) and the chronicity of the disease could be evaluated better with 99mTc colloid. Among the patients with different stages of liver cirrhosis, however, 99mTc IDA significantly discriminated the severity of the hepatic disease. These results suggest that 99mTc IDA may be used to determine the degree of functional disorder in acute hepatic disease and evaluate the severity of diffuse hepatic disease, whereas 99mTc colloid can effectively evaluate the potential etiology and chronicity of the disease.
对96例患有各种弥漫性肝病的患者使用99m锝胶体和99m锝亚氨基二乙酸(IDA)进行观察,重点关注疾病过程的潜在病因及其慢性程度和严重程度。与99m锝胶体相比,99m锝IDA对急性肝病的存在情况显示出更高的敏感性。另一方面,在慢性肝病中,99m锝胶体和99m锝IDA表现出相似的敏感性。使用99m锝胶体可以更好地评估疾病过程的潜在病因(鉴别诊断)和疾病的慢性程度。然而,在不同阶段肝硬化的患者中,99m锝IDA能显著区分肝病的严重程度。这些结果表明,99m锝IDA可用于确定急性肝病的功能障碍程度并评估弥漫性肝病的严重程度,而99m锝胶体可以有效评估疾病的潜在病因和慢性程度。